Loading...
•
Jun 30, 2020
Standard Biotool Q2 2020 Earnings Report
Reported an 8 percent decrease in revenue, amounting to $26.1 million, and filed for FDA Emergency Use Authorization for COVID-19 Saliva-based Test.
Key Takeaways
Fluidigm Corporation announced financial results for the second quarter ended June 30, 2020. The company has pivoted to meet testing and immune profiling research needs brought on by the pandemic. They filed for Emergency Use Authorization for their extraction-free saliva test and were selected for a project to expand COVID-19 testing under the National Institutes of Health Rapid Acceleration of Diagnostics initiative.
Revenue decreased 8 percent to $26.1 million.
Filed for Emergency Use Authorization for COVID-19 Saliva-based Test.
Selected for $37 Million Project under National Institutes of Health RADx Initiative.
Product and service margin was 52.5 percent.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...